| 1 |
Antonovych TT,Lin RC, Parrish E. Light chain deposits in multiple myeloma [J]. Lab Invest,1974,30:370A.
|
| 2 |
Randall RE, Williamson WC Jr, Mullinax F, et al. Manifestations of systemic light chain deposition [J]. Am J Med, 1976, 60(2):293-299.
|
| 3 |
Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis [J]. Ann Intern Med,1990,112(6):455-464.
|
| 4 |
Aucouturier P, Khamlichi AA, Touchard G, et al. Heavy-chain deposition disease [ J]. N Engl J Med, 1993, 329 (19):1389-1393.
|
| 5 |
Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum [J]. J Am Soc Nephrol,2001,12(7):1482-1492.
|
| 6 |
Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution [J]. Clin J Am Soc Nephrol, 2012, 7(2):231-239.
|
| 7 |
Bruneval P,Foidart JM,Nochy D,et al. Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus [J]. Hum Pathol, 1985,16(5):477-484.
|
| 8 |
Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage [J]. Kidney Int,2005,68(4):1590-1603.
|
| 9 |
Keeling J, Teng J, Herrera GA. AL-amyloidosis and lightchain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells[J]. Lab Invest,2004,84(10):1322-1338.
|
| 10 |
Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light(heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy [J]. Clin J Am Soc Nephrol,2006,1(6):1342-1350.
|
| 11 |
Khurana R, Gillespie JR, Talapatra A, et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates [J]. Biochemistry, 2001, 40(12): 3525-3535.
|
| 12 |
Denoroy L, Dé ret S, Aucouturier P. Overrepresentation of the V kappa IV subgroup in light chain deposition disease [J]. Immunol Lett,1994,42(1-2):63-66.
|
| 13 |
Moulin B, Deret S, Mariette X, et al. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1 [J]. J Am Soc Nephrol,1999,10(3):519-528.
|
| 14 |
Kambham N, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: the disease spectrum [J]. Am J Kidney Dis,1999,33(5):954-962.
|
| 15 |
Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders[J]. Semin Nephrol,2002,22(4):319-330.
|
| 16 |
Rathi M, Ramachandran R, Kohli HS, et al. An unusual cause of gross hematuria and renal dysfunction in a young male [J], Indian J Nephrol,2013,23(5):371-374.
|
| 17 |
Heilman RL,Velosa JA,Holley KE,et al. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease [J]. Am J Kidney Dis,1992,20(1):34-41.
|
| 18 |
Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: A poorly recognized pattern of renal disease in patients with plasma cell dyscrasia [J]. Arch Pathol Lab Med, 2006, 130(2):165-169.
|
| 19 |
Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine [J]. Clin Chem,2009,55(3):499-504.
|
| 20 |
Gerth J, Sachse A, Busch M, et al. Screening and differential diagnosis of renal light chain-associated diseases[J]. Kidney Blood Press Res,2012,35(2):120-128.
|
| 21 |
Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement:clinical characteristics and prognostic factors [J]. Am J Kidney Dis,2003,42(6):1154-1163.
|
| 22 |
Komatsuda A, Maki N, Wakui H, et al. Development of systemic lambda-light chain amyloidosis in a patient with gamma-heavy chain deposition disease during long-term follow-up [J]. Nephrol Dial Transplant,2005,20(2):434-437.
|
| 23 |
Nakatsuka A, Maeshima Y, Sarai A, et al. A case of monoclonal immunoglobulin light- and heavy-chain deposition disease exhibiting atypical deposition with fibrillary structures,successfully treated with chemotherapy [J]. Clin Nephrol,2005,64(3):221-227.
|
| 24 |
Weichman K, Dember LM, Prokaeva T, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation [J]. Bone Marrow Transplant,2006,38(5):339-343.
|
| 25 |
Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease [J]. Kidney Int,2004,65(2):642-648.
|
| 26 |
Firkin F, Hill PA, Dwyer K, et al. Reversal of dialysis dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation [J]. Am J Kidney Dis,2004,44(3):551-555.
|
| 27 |
Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease-diagnosis and treatment [J]. Clin J Am Soc Nephrol,2007,2(4):858-867.
|
| 28 |
Gerth J, Sigusch H, Illner N, et al. Renal manifestations of light chain associated diseases-epidemiology and prognosis [J]. Dtsch Med Wochenschr,2013,138(7):305-312.
|
| 29 |
Hassoun H, Flombaum C, D'Agati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease [J].Bone Marrow Transplant,2008,42(6):405-412.
|
| 30 |
Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease [J]. Am J Kidney Dis,2004,43(1):147-153.
|
| 31 |
Stratta P, Gravellone L, Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience [J]. Crit Rev Oncol Hematol,2011,79(1):31-42.
|